Skip to content
Companies

PhAST

Single-cell imaging for fast antibiotic susceptibility tests

  • Boston, MA
  • Biotech

Raised to date

$3.5M

of $8M offered across 1 Form D filing

Still open
$4.5M
Investors
5
Last filed
Apr 24, 2025

About

PhAST Corp. is a biotechnology company specializing in the transformation of infectious disease diagnostics through innovative rapid diagnostic technology. With a focus on minimizing turnaround times for pathogen detection and testing, PhAST Corp. aims to enhance patient care by enabling timely treatment decisions.

PhAST Corp. stands out by significantly reducing the diagnosis time for infections from days to minutes through its advanced imaging technology.

Funding

  • EquityFiled Apr 24, 2025Form D
    $3.5M/ $8M

Product

Rapid Diagnostic Technology

Diagnostic Technology

PhAST Corp. is developing a rapid diagnostic technology that utilizes single-cell imaging to provide real-time, actionable data about microorganisms. This innovative approach focuses on closely analyzing individual cells to enhance the speed and accuracy of pathogen detection and antibiotic susceptibility testing.

  • Single-cell imaging for precise analysis
  • Real-time diagnostic results
  • Enhanced speed for faster clinical decision-making

Built for

Clinical laboratories, hospitals, research institutions, biotechnology firms

People on file